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Palladium(II)Abstract Pd(II) complexes of 3-formyl chromone Schiff bases such as 3-((2-hydroxyphenylimino)
methyl)-4H-chromen-4-one (HL1), 2-((4-oxo-4H-chromen-3-yl)methylneamino)benzoic acid (HL2),
3-((3-hydroxypyridin-2-ylimino)methyl)-4H-chromen-4-one (HL3), 3-((2-mercaptophenylimino)
methyl)-4H-chromen-4-one (HL4) and 3-((pyridine-2-ylimino)methyl)-4H-chromen-4-one (L5) have
been synthesised and characterised by elemental analysis, molar conductivity, IR, electronic, mag-
netic, TG–DTA, powder XRD and ﬂuorescence spectral data. From the analytical, electronic and
magnetic data square-planar geometry has been proposed for all the Pd(II) complexes. Powder
XRD studies indicate the crystalline state of the Pd(II) complexes. The antimicrobial activity of
Pd(II) complexes was performed against two Gram(ve), two Gram(+ve) and fungal microorgan-
isms and the results indicate that, complexes show better microbial inhibition activity than the
ligands. Pd(II) complex of HL1 displayed comparable antioxidant activity with reference to the
standard drug (BHT). Agarose gel electrophoresis assay demonstrates the ability of complexes to
cleave the pUC19 plasmid DNA. The cytotoxicity was tested by the MTT assay. The results indi-
cate that the complexes exert cytotoxic effects against tested cell lines but their cytotoxicity is less
than that of cisplatin.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Formyl chromone Schiff bases have been the centre of attrac-
tion for many workers in the current research due to their mis-
cellaneous activities. Chromones are naturally occurring
compounds which are able to cause cytotoxic effect in various
types of cells. They are widely known to have anticancer, anti-
oxidant, antiproliferative, antiHIV, antiinﬂammatory, and
many other activities (Martens and Mithofer, 2005; Di Braccio
et al., 2003; Middleton et al., 2000). Since the last decade, me-
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Figure 1 Structures of ligands.
Pd(II) complexes bearing chromone based Schiff bases: Synthesis, characterisation and biological activity studies 641tal coordination chemistry has been one of the most efﬁcient
strategies in the design of drugs (Jones and Thornbak, 2007).
Many literature reports revealed that chromone and its deriv-
atives are able to form stable and coloured complexes with var-
ious metal ions (Anitha et al., 2012; Li and Yang, 2010).
According to literature reports, metal complexes of the chro-
mone moiety possess various biological activities in some cases
comparable with cisplatin (which is an effective anticancer
drug) (Grazul and Budzisz, 2009) and some metal complexes
which are connected with reactions generating free radicals,
may in some cases obtain additional antioxidant ability
(Kostyuk et al., 2001; Grazul et al., 2012). These metal com-
plexes are also used in various ﬁelds (Nijhawan and Kakkar,
1998).
A large number of platinum and palladium complexes con-
taining amine based ligands have become the subject of inten-
sive research, since they are structurally related to cisplatin.
The success of cisplatin and other Pt(II) complexes in the treat-
ment of ovarian, testicular, neck and head, oesophageal and
non-small cell lung cancers (Todd and Lippard, 2009;
Eastman, 1999; Montana and Batalla, 2009; Abu-Surrah and
Kettunen, 2006; akomska, 2009) and similar properties of
Pt(II) and its congener Pd(II), have led to a large effort in
the search to ﬁnd Pd(II) antitumour drugs that are effective
against Pt(II) resistant therapies and that have fewer side ef-
fects (Garouﬁs et al., 2009; Abu-Surrah et al., 2008; Gao
et al., 2009; Sˇtarha et al., 2009). The main target of chemother-
apy is the destruction of tumour cells without any undue inﬂu-
ence on proper cells. Compared to palladium and platinum
complexes, palladium complexes are hydrolyzed 105 times fas-
ter than their corresponding platinum analogues, which could
lead to the hydrolysis of Pd(II) complexes before they reach
their target DNA (Polyanskaya et al., 2010). Pd(II) complexes
also posses antimicrobial and antioxidant activity etc. (Spera
et al., 2011; Ramachandran et al., 2012). This has provoked
interest in the design of Pd(II) complexes.
As part of our on-going research work on the synthesis of
metal complexes with Schiff bases derived from formyl chro-
mone and aromatic amines i.e. 3-((2hydroxyphenylimino)
methyl)-4H-chromen-4-one (HL1), 2-((4-oxo-4H-chromen-3-
yl)methylneamino)benzoic acid (HL2), 3-((3-hydroxypyridin-
2-ylimino)methyl)-4H-chromen-4-one (HL3), 3-((2-mercap-
tophenylimino) methyl)-4H-chromen-4-one (HL4) and 3-((pyr-
idine-2-ylimino)methyl)-4H-chromen-4-one (L5) (Kavitha and
Laxma Reddy, 2016; Kavitha et al., 2013a,b), we present here
the preparation, characterisation and evolution of biological
activities (antimicrobial, antioxidant, cytotoxicity and DNA
cleavage) of Pd(II) complexes with the 3-formyl chromone
Schiff base ligands (HL1, HL2, HL3, HL4 and L5).
2. Experimental
2.1. Reagents and equipments
All chemicals and solvents used were of AR grade. Palladium
dichloride was obtained from Jhonson Matthew Chemicals
(England).
The UV–Vis spectra of the ligands and their metal com-
plexes were recorded on an Analytikzena Specord 205 UV–
Vis spectrophotometer. Molar conductance of the complexes
was measured in DMF at 1 · 103 M using a Digisun conduc-
tivity meter. Elemental analysis (C, H, and N) was performedusing Perkin Elmer CHN analyser. The chloride ion was
estimated by the Volhard’s method (Vogel, 1961). The IR
pectra (4000–400 cm1) in KBr discs were recorded on TEN-
SOR 2 spectrophotometer. Thermal studies of the complexes
were carried out on a Perkin Elmer diamond TGA instrument
at a heating rate of 10 C and a nitrogen ﬂow rate of 20 mL/
min. The magnetic susceptibilities of Pd(II) complexes were
measured with a Sherwood scientiﬁc balance. Fluorescence
spectra were recorded using Perkin Elmer LS 55 ﬂuorescence
spectrometer. The X-ray powder diffraction analysis was car-
ried out by using Xpert-Pro X-ray diffractometer using Cu-
Ka (1.5360 A˚) radiation.
2.2. Synthesis of ligands
Schiff base ligands HL1, HL2, HL3, HL4 and L5 (Fig. 1) were
synthesised and characterised according to the literature (Sigg
et al., 1982; Khan et al., 2010; Kavitha et al., 2012, 2013b;
Kavitha and Laxma Reddy, 2016).
2.3. Synthesis of Pd(II) complexes
All the palladium(II) complexes were prepared using the gen-
eral procedure as given below. PdCl2 solution in 0.1 M HCl
642 P. Kavitha, K. Laxma Reddy(1 mM) was taken and treated with an equal volume of water.
The hot methanolic ligand solution (2 mM) was added drop
wise to the hot metal salt solution. The reaction mixture was
stirred at room temperature for 30 min. The coloured complex
thus separated out was ﬁltered, washed several times with hot
water and methanol until the washings were free from excess
ligand and palladium chloride and dried in vacuo.
2.4. Pharmacology studies
2.4.1. Antimicrobial activity
In vitro antimicrobial activity of the Pd(II) complexes was
evaluated against Proteus vulgaris, Klebsiella pnuemoniae as
gram-negative, Staphylococcus aureus, Bacillus subtili as
gram-positive bacteria cultures where as Candida albicans fun-
gi culture using antibiotics kanamycin and clotrimazole are the
standards. The disc diffusion method was adopted for activity
measurements. Standard inoculums, 1–2 · 107 cfu/mL 0.5 Mc
Farland standards (Stemper and Matsen, 1970) were intro-
duced onto the surface of the sterile nutrient agar plate and
evenly spread by using a sterile glass spreader. Sterile antibiotic
discs (6 mm in diameter, prepared using Whatmann No. 1 pa-
per) were placed over the nutrient agar medium. Each disc was
spread by 100 lg of the compounds (initially dissolved in
DMSO). The plates were incubated with bacterial cultures
for 24 h at 37 C and fungal cultures at 25 C for 48 h. The
activity of the compounds was determined by measuring the
diameter of inhibition zone in ‘millimetres’ and compared with
standard antibiotics. DMSO (which has no activity) and stan-
dard antibiotics were used as negative and positive controls for
antimicrobial activity studies. The activity results are calcu-
lated as a mean of triplicates.
Minimum inhibitory concentrations (MIC) of the com-
plexes which showed antimicrobial activity were determined
using the literature method (Shankar et al., 2009). All the com-
pounds diluted within the range of 100–10 lg/mL were mixed
in nutrient broth and 0.1 mL of active inoculums was added to
each tube. The tubes were incubated aerobically at 37 C for
bacteria and 25 C for fungi for 24 h. The lowest concentration
of the compound that completely inhibited bacterial growth
(no turbidity) in comparison to control was regarded as MIC.
2.4.2. Free radical scavenging activity
The antioxidant activity of Pd(II) complexes was evaluated in
DPPH free radical scavenging method.
Test samples were applied on a TLC plate as a spot using
mobile phase methanol:acetonitrile (7:1). It was allowed to de-
velop the chromatogram for 30 min. After the completion of
the chromatogram, the plate was sprayed with DPPH
(0.2% w/v). The colour change (yellow spot on purple back-
ground on TLC plate) is an indication of the presence of anti-
oxidant activity.2.4.2.1. Quantitative analysis. 0.004% solution of the DPPH
radical in methanol was prepared, and 3 mL of this solution
was added to 1 mL of the compounds (stock solution is
10 mg/10 mL). The mixture was shaken vigorously and al-
lowed to stand at room temperature for 30 min. Then, the
absorbance was measured at 517 nm using a spectrophotome-
ter. DPPH solution was used as the control without the test
compounds, whereas methanol was used as the blank.Lowering of the absorbance of the test compounds indicates
higher free radical scavenging activity. BHT is used as the stan-
dard. The capability to scavenge the DPPH radical was calcu-
lated using the following equation:
Scavenging activityð%Þ ¼ ðA0  AiÞ
A0
 
 100
where A0 is the absorbance of the control solution, and Ai is
the absorbance in the presence of sample solutions or stan-
dards for positive control. IC50 values were calculated, which
exhibited signiﬁcant activity.
2.4.3. Cytotoxicity
2.4.3.1. Solutions. The complexes were dissolved in DMSO at a
concentration of 5 mg/100 mL as stock solution, and diluted in
a culture medium at concentrations of 1, 10 and 100 lg/mL as
working solution.
2.4.3.2. Cell culture and drug treatment. Raw 264.7 cell line
(murine macrophage cell line), MCF-7 (human breast carci-
noma cell line) and COLO 205 (human colon carcinoma cell
line) were obtained from NCCS Pune. Cell lines were main-
tained in Dulbecco’s Modiﬁed Eagle Medium (DMEM) sup-
plemented with 10% fetal bovine serum, amphotericin (3 lg/
mL), gentamycin (400 lg/mL), streptomycin (250 lg/mL)
and penicillin (250 Units/mL) in a carbon dioxide incubator
at 5% CO2. About 700 cells per well were seeded in 96 well
plates using a culture medium. The cell viability was tested
using trypan blue dye with the help of a haemocytometer
and 95% of the viability was conﬁrmed. After 24 h, the new
medium with compounds in the concentration of 1, 10 and
100 lg /mL was added at respective wells and kept in incuba-
tion for 48 h. After incubation, MTT assay was performed.
Later than, 48 h of the drug treatment, the medium was chan-
ged again for all groups and 10 lL of MTT (3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (5 mg/mL
stock solution) was added and the plates were incubated for
an additional 4 h. The medium was discarded and formazan
blue, which was formed in the cells, was dissolved in 50 lL
of DMSO. The optical density was measured at 570 nm. The
percentage toxicity was calculated by using the following for-
mula (Sathiyaraj et al., 2012).
%Toxicity ¼ 1 ðtreated cells=untreated cellsÞ  100
IC50 of compounds were calculated using Graphpad PRISM
software tool.
2.4.4. DNA cleavage activity
Agarose gel electrophoresis was used to study the DNA cleav-
age activity of the Pd(II) complexes. pUC19 plasmid was cul-
tured, isolated and used as DNA for the experiment. Test
samples (1 mg/mL) were prepared in DMF. 25 lg of the test
samples were added to the isolated plasmid and incubated
for 2 h at 37 C. After incubation, 30 lL of plasmid DNA sam-
ple mixed with bromophenol blue dye was loaded into the elec-
trophoresis chamber wells along with control (plasmid DNA
in DMF without test sample) and standard DNA markers. Fi-
nally, it was loaded onto an agarose gel and electrophoresed at
a constant voltage of 50 V for 30 min. After the run, gel was
removed and stained with 10.01 lg/mL ethidium bromide
and image was taken in Versadoc (Bio-Rad) imaging system.
Figure 2 Electronic spectra of (a) HL3, and (b) Pd(II) complex.
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The same procedure was followed in the presence of oxidising
agent H2O2 (5 lL, 500 lM) also.
3. Results and discussion
All Pd(II) complexes are coloured, non-hygroscopic, stable in
air, insoluble in water and many common organic solvents
but soluble in DMF and DMSO. The analytical, physical
and molar conductivity data of the metal complexes are given
in Table 1. The analytical data revealed that the metal to igand
molar ratio is 1:1 for all the complexes except the complex 5.
However, 1:2 M ratio was found in the case of complex 5.
The molar conductance values of all Pd(II) complexes except
the complex 5 in DMF at 1 · 103 M are found to be in the
range 10–20 X1 cm2 mol1 indicating their non-electrolytic
nature. However, molar conductance value for the complex 5
in DMF is 128 X1 cm2 mol1 which indicates its 1:2 electro-
lytic nature (Geary, 1971).
3.1. Electronic spectra
The absorption spectra of ligands and their Pd(II) complexes
were recorded in DMF solution in the wavelength range of
200–1100 nm. The bands in the UV–visible spectra of all the
complexes were assigned upon comparison with the spectra
of their corresponding ligands (HL1–L5). The absorption spec-
trum of HL3 and its Pd(II) complex is shown in Fig. 2. Free
ligands showed the absorption bands between 25,000 to
27,000 cm1 and 31,000 to 34,000 cm1 and are assigned to
nﬁ p* and pﬁ p* transitions, respectively. These bands are
shifted to the lower energy region upon complexation with
the metal ion. All Pd(II) complexes exhibit one band in the vis-
ible region at around 20,000 to 25,000 cm1 and are assigned
to 1A1g ! 1Eg transition characteristic of square-planar geom-
etry (Al-Noaimi et al., 2012). All the palladium complexes are
also found to be diamagnetic which also supports the square-
planar geometry of the complexes.
3.2. IR spectra
The infrared spectra provide important information about the
skeleton of the complexes. The main stretching frequencies of
the Pd(II) complexes are presented in Table 2. The t(C‚O) ofTable 1 Physical, analytical and molar conductivity data of Pd(II)
Complex no. Molecular formula Colour %Yield % F
C
(1) [Pd(L1)Cl] Orange red 71 47.4
(47.3
(2) [Pd(L2)Cl] Yellow 65 47.5
(47.0
(3) [Pd(L3)Cl] Dark red 90 43.4
(44.2
(4) [Pd(L4)Cl] Brick red 82 45.5
(45.5
(5) [Pd(L5)2]ÆCl2 Green 78 52.9
(53.1carbonyl group of the ligands appear in the range of 1650–
1620 cm1, while in their Pd(II) complexes the band is shifted
to lower wavenumber by 6–40 cm1 (Wang et al., 2008). It
shows that the oxygen of the carbonyl group takes part in
coordination in all the complexes. The t(C‚N) of azomethine
group of ligands show a band in the region of 1600–1550 cm1
and it is shifted to 16–39 cm1 in Pd(II) complexes towards
lower wave number region, indicating that the nitrogen of azo-
methine group is involved in the coordination (Li and Yang,
2010). The bands at 3241 and 3246 cm1 are due to t(OH)
group of HL1 and HL3 ligands. It disappeared in their corre-
sponding Pd(II) complexes, indicating the participation of oxy-
gen atom of the OH group in coordination with deprotination.
A band at 1365 cm1 in HL2 ligand is due to the t(C–O) of car-
boxylic group, in its complex it was shifted by 16 cm1 suggest-
ing the oxygen atom of carboxylic group participated in the
coordination (Olczak-Kobza and Mrozek, 2009). The SH
stretching vibration, t(SH), is not useful in ascertaining its
coordination in the complexes, since it displayed very weak
bands in HL4 ligand spectra. However, the participation of
the SH group in chelation is ascertained from the shift of the
t(C–S) by 59 cm1 to lower wavenumber region in the spectra
of its corresponding Pd(II) complex (Mohamed et al., 2006).
Further the conﬁrmation of N, O and Cl in coordination is
demonstrated by new bands in the range of 500–300 cm1
(Patel et al., 2012).complexes.
ound (calcd.) Molar conductivity
(ohm1 mol1 cm2)
H N S Cl
5 2.21 3.10 8.85 11
0) (2.46) (3.44) (8.74)
5 2.19 3.18 8.01 20
1) (2.30) (3.22) (8.18)
7 2.28 6.79 8.98 15
3) (2.21) (6.88) (8.72)
9 2.09 3.15 7.68 8.38 13
0) (2.37) (3.31) (7.58) (8.41)
8 2.25 8.62 10.78 128
4) (2.95) (8.26) (10.48)
Table 2 Infrared spectral data and their assignments of ligands and their Pd(II) complexes.
Compound t(C‚O) (c pyrone) t(C‚N) t(CO) (carboxylate) t(C–S) t(M–N) t(M–O) t(M–Cl)
HL1 1643 1605
HL2 1651 1605 1365
HL3 1647 1591
HL4 1622 1597 790
L5 1654 1596
[Pd(L1)Cl] (1)
1637 1571 489 390 348
[Pd(L2)Cl] (2) 1611 1566 1349 470 360 346
[Pd(L3)Cl] (3) 1634 1575 490 375 332
[Pd(L4)Cl] (4) 1614 1566 731 485 399 314
[Pd(L5)2]ÆCl2 (5) 1611 1575 458 357 –
Figure 3 TG graphs of (a) [Pd(L1)Cl], and (b) [Pd(L5)2]ÆCl2.
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Figure 4 Structures of Pd(II) complexes, (a) Complexes 1–4, and
(b) Complex 5.
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The thermal decomposition studies of the Pd(II) complexes
were carried out in nitrogen atmosphere in the temperature
range of 30–1000 C. The TG graphs of complexes 1 and 5
are given in Fig. 3. In the case of complex 1 there is no weight
loss up to 185 C. However, all other complexes (2–5) undergo
ﬁrst step decomposition with a weight loss of 7.58–16.55%
(calcd. 8.18–15.72%) in between 30 and 284 C due to the
removal of chloride ions (lattice and coordinated). All the
complexes (1–5) show the second decomposition step 61.94–
66.89% (calcd. 61.10–66.21%) in the temperature range of
196–710 C due to the decomposition of organic part of the
complexes. The ﬁnal amount of residue of all complexes is
close to calculated mass of palladium oxide.
On the basis of the above studies (elemental, conductivity,
electronic and infrared data) the following structure (Fig. 4)
may be proposed for all the Pd(II) complexes.
3.4. Fluorescence
The solid state emission spectra of Pd(II) complexes were stud-
ied at room temperature. The emission spectra of complexes
1–5 are illustrated in Fig. 5 and the excitation and emission
data are listed in Table 3. All Pd(II) complexes exhibit weak
ﬂuorescence except complex 4 compared to their correspond-
ing ligands when excited at the absorption wavelengths inthe range of 307–453 nm. However formyl chromone Schiff
base ligands are highly emissive excitation upon different
wavelengths (Kavitha et al., 2013a). It was observed that the
emission spectra of metal complexes that are originated may
be from the formyl chromone moiety. The emission intensity
of the complexes signiﬁcantly decreases compared to that of
the corresponding ligands, but the emission intensity of com-
plex 4 is much higher than those of other four complexes. This
enhancement in the emission intensity may be due to low-lying
Figure 5 Fluorescence spectra of all Pd(II) complexes, (a)
[Pd(L1)Cl] (b) [Pd(L2)Cl] (c) [Pd(L3)Cl] (d) [Pd(L4)Cl], and (e)
[Pd(L5)2]ÆCl2.
Table 3 Excitation and emission wavelengths of Pd(II)
complexes.
Compound Excitation
wavelength
(nm)
Emission
wavelength (nm)
[Pd(L1)Cl] (1) 453 551, 621sh, 747sh
[Pd(L2)Cl] (2) 381 481(sh), 558
[Pd(L3)Cl] (3) 451 549 sh, 618, 743sh
[Pd(L4)Cl] (4) 307 469
[Pd(L5)2]ÆCl2 (5) 384 484, 526sh, 634sh
Table 4 PXRD spectral data of Pd(II) complexes.
Complexes 2h d Relative
intensity
Full width at
half maximum
[Pd(L1)Cl] (1) 28.83 3.094 100 0.205
[Pd(L3)Cl] (3) 30.45 2.933 100 0.183
[Pd(L5)2]ÆCl2 (5) 46.44 1.953 100 0.438
Table 5 MIC values of antimicrobial activity of Pd(II)
complexes.
Compound Bacillus
subtilis
Staphylococcus
aureus
Proteus
vulgaris
Klebsiella
pneumoniae
Candida
albicans
HL1 – – – – –
HL2 80 80 80 80 80
HL3 – – – – –
HL4 – – – – –
L5 53 53 53 53 53
[Pd(L1)Cl] (1) 50 60 55 75 60
[Pd(L2)Cl] (2) 55 55 55 55 55
[Pd(L3)Cl] (3) – – – – –
[Pd(L4)Cl] (4) – – – – –
[Pd(L5)2]ÆCl2
(5)
80 80 – – –
Kanamycin 4 10 8 11 –
Clotrimazole – – – – 10
Pd(II) complexes bearing chromone based Schiff bases: Synthesis, characterisation and biological activity studies 645excited state orbital of complex 4 (Guney et al., 2010). Litera-
ture reports revealed that, blue/red shift of emission maxima
was observed, when ligands are coordinated with the metal
ions (Jin et al., 2012; Guney et al., 2011).
3.5. X-ray powder diffraction
Single crystals of the studied complexes could not be obtained,
because the complexes are insoluble in most common organicFigure 6 PXRD patterns of (a) [Psolvents except DMF and DMSO. The X-ray powder diffrac-
tion patterns of the Pd(II) complexes were recorded over
2h= 10–80. The diffractograms of the complexes are dis-
played in Fig. 6. The diffraction data like angle (2h), interpla-
nar spacing (d), and relative intensity (%) have been
summarized in Table 4. From the data, all Pd(II) complexes
show sharp crystalline peaks except complex 2 and 4, indicat-
ing their crystalline nature. However complex 2 and 4 show
amorphous nature. The XRD patterns of all complexes are
very similar and suggest that the complexes have similar struc-
ture. The average crystallite sizes of the complexes dxrd were
calculated using the Sherrers formula (Warren, 1990). Com-
plexes 1, 3 and 5 have a crystallite size of 41, 46 and 20 nm
respectively, suggesting that the complexes are in a nano crys-
talline phase.d(L2)Cl], and (b) [Pd(L5)2]ÆCl2.
Table 6 IC50 values of antioxidant activity of Pd(II)
complexes.
Compound IC50 (lg/mL)
[Pd(L1)Cl] (1) 0.90
[Pd(L3)Cl] (3) 1.31
BHT 0.67
Table 7 IC50(lg/mL) values of cytotoxicity of Pd(II)
complexes.
Compound Raw MCF-7 COLO 205
[Pd(L1)Cl] (1) 44.0 62.3 63.9
[Pd(L2)Cl] (2) 76.0 60.1 63.1
[Pd(L3)Cl] (3) 51.0 49.9 56.2
[Pd(L4)Cl] (4) 102.4 72.2 59.9
[Pd(L5)2]ÆCl2 (5) 45.2 25.5 51.0
Cisplatin 1.2 1.7 5.6
646 P. Kavitha, K. Laxma Reddy3.6. Pharmacology
3.6.1. Antimicrobial activity
The minimum inhibitory concentration (MIC) values of Pd(II)
complexes are given in Table 5. In vitro antimicrobial screening
results (Table 5), Pd(II) complexes are potent than their corre-
sponding ligands and compared to the antibiotics, moderately
active against tested microorganisms. The activity of the li-
gands has enhanced on complexation, which can be explained
on the basis of Tweedy’s chelation theory and Overtones con-
cept (Bahafﬁ et al., 2012; Mahalakshmi and Rajavel, 2014).
Among all the Pd(II) complexes, complex 2 showed better
activity against all microorganisms. Complex 3 and 4 exhibit
very low activity against all bacteria and fungi strains. Com-
plex 5 is active against only B. subtili and S. aureus.
3.6.2. Free radical scavenging activity
The stable DPPH radical scavenging is a widely used method
to evaluate antioxidant activities, in a relatively short time
compared with other methods. The DPPH radical contains
an odd electron responsible for absorbance at 517 nm. When
the reaction between antioxidant molecules and DPPH radical
results in the scavenging of the radical by hydrogen or electron
donation, the antioxidants cause to a decrease of the absor-
bance of the DPPH radical. This is visually noticeable as a dis-a
Figure 7 Gel electrophoresis graphs of Pd(II) complexes. (a) DNA cle
Lane 2. DNA+ Complex 2; Lane 3. DNA+ Complex 3; Lane 4.
DNA+ FeSO4; Lane control. DNA alone (without complexes).
DNA+ Complex 1 + H2O2; Lane 2. DNA+ Complex 2 + H2O2;
4 + H2O2; Lane 5. DNA+ Complex 5 + H2O2; Lane control. DNAcoloration from purple to yellow. Hence, DPPH is usually
used as a substrate to evaluate the activity of antioxidants
(Ceyhan et al., 2011). IC50 values of antioxidant activity of
Pd(II) complexes were reported in Table 6. These results indi-
cate that the complexes 1 and 3 have a noticeable activity com-
pared to the remaining Pd(II) complexes. The complexes 2, 4
and 5 do not show antioxidant activity. Among all the com-
plexes, complex 1 showed activity comparable to BHT
(standard).
3.6.3. Cytotoxicity
The cytotoxicity of complexes 1–5 was tested on three cell
lines, that is murine macrophage cell line Raw 264.7, human
breast cancer cell line MCF-7 and human colon carcinoma cell
line COLO 205. Cisplatin was used as a positive reference. The
activity is expressed as the concentration of the complexes re-
quired to inhibit the cellular survival fraction to 50% (IC50)
after exposure to the compounds for 48 h. The results are pre-
sented in Table 7.
As shown in Table 7, Pd(II) complexes are found to be
much less active when compared to cisplatin against three cell
lines. Among all complexes pyridine ring containing complexes
i.e. complexes 3 and 5 are potent.3.6.4. Cleavage of pUC19 DNA by Pd(II) complexes
The DNA cleavage reaction of Pd(II) complexes was moni-
tored by agarose gel electrophoresis. When circular plasmid
DNA is subject to electrophoresis, relatively fast migration will
be observed for the intact supercoiled form (Form I). The
slower-moving migration is the open circular form (Form II)
which was generated from the supercoil when scission occurred
on one of its strands, and a linear form (Form III) which was
generated when both strands were cleaved and migrates be-
tween Form I and II (Seng et al., 2008). To investigate the
mechanism of cleavage studies of Pd(II) complexes, DNA
cleavage activity was observed in the presence and absence
of H2O2 as an oxidant. The gel electrophoretic separation of
pUC19 DNA after incubation with all Pd(II) complexes is de-
picted in Fig. 7a and b. From Fig. 7a, no DNA-cleavage was
observed for the control in which the metal complex was ab-
sent (lane control). When the pUC19 DNA was treated with
the complexes (lane 1–5), no bands were observed in the lane
1, 3 and 5 probably due to the complete degradation of
DNA into small pieces. It is reasonably expected due to the
hydrolytic cleavage (absence of any reducing or oxidisingb
avage studies in the absence of H2O2. Lane 1. DNA+ Complex 1;
DNA+Complex 4; Lane 5. DNA+ Complex 5; Lane FeSO4.
(b) DNA cleavage studies in the presence of H2O2. Lane 1.
Lane 3. DNA+ Complex 3 + H2O2; Lane 4. DNA+ Complex
+ H2O2.
Pd(II) complexes bearing chromone based Schiff bases: Synthesis, characterisation and biological activity studies 647agents). In lanes 2 and 4 no difference was observed compared
to the control band, which indicates the inactivity of complexes
2 and 4 respectively. In the presence of H2O2 (Fig. 7b) complex
4 showed complete DNA cleavage and complex 2 showed par-
tial cleavage. In this case, oxidative DNA cleavage was ob-
served, which may be due to the formation of hydroxyl
radicals. Many literature reports revealed the mechanism of
the DNA cleavage of the metal complexes in the presence of
oxidant H2O2 (Arish and Sivasankaran Nair, 2011).
4. Conclusions
A series of Pd(II) complexes with tridentate/bidentate Schiff
base ligands derived from 3-formyl chromone and aromatic
amines were synthesised. Complexes were characterised by
physico analytical techniques. Electronic and magnetic data
suggest the square-planar geometry for all Pd(II) complexes.
Powder XRD data revealed the crystalline nature of the com-
plexes. All complexes displayed solid state ﬂuorescence at
room temperature. Pd(II) complexes exhibit less to moderate
antimicrobial activity. Complex 1 was considered as lead com-
pounds worthy of further structural optimization and develop-
ment as potential antioxidants. The successful DNA cleavage
was observed for complexes 1, 3 and 5 without any additives.
But in the case of complexes 2 and 4 effective DNA cleavage
was observed in the presence of H2O2. The cytotoxicity results
of the complexes are not satisfactory when compared to cis-
platin (anticancer drug).Acknowledgements
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